BML Capital Management LLC Sells 6,537 Shares of CalciMedica, Inc. (NASDAQ:CALC)

BML Capital Management LLC reduced its position in shares of CalciMedica, Inc. (NASDAQ:CALC) by 4.1% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 153,887 shares of the company’s stock after selling 6,537 shares during the quarter. CalciMedica makes up about 0.4% of BML Capital Management LLC’s holdings, making the stock its 22nd biggest holding. BML Capital Management LLC owned about 1.43% of CalciMedica worth $682,000 at the end of the most recent reporting period.

Separately, Atria Investments Inc raised its holdings in CalciMedica by 136.5% during the 3rd quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock valued at $117,000 after buying an additional 15,296 shares during the last quarter.

Insiders Place Their Bets

In other CalciMedica news, CEO A. Rachel Leheny purchased 20,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was bought at an average cost of $3.75 per share, for a total transaction of $75,000.00. Following the purchase, the chief executive officer now directly owns 130,926 shares in the company, valued at $490,972.50. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other CalciMedica news, Director Robert N. Wilson purchased 54,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was bought at an average cost of $3.72 per share, for a total transaction of $200,880.00. Following the purchase, the director now directly owns 364,196 shares in the company, valued at $1,354,809.12. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO A. Rachel Leheny purchased 20,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was acquired at an average price of $3.75 per share, with a total value of $75,000.00. Following the completion of the purchase, the chief executive officer now owns 130,926 shares in the company, valued at $490,972.50. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 312,944 shares of company stock worth $1,172,910. 41.55% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Separately, HC Wainwright decreased their price objective on shares of CalciMedica from $20.00 to $16.00 and set a “buy” rating for the company in a report on Monday, November 4th.

CalciMedica Trading Down 1.1 %

NASDAQ CALC traded down $0.04 during trading on Tuesday, hitting $3.46. The company had a trading volume of 9,764 shares, compared to its average volume of 36,100. CalciMedica, Inc. has a one year low of $2.68 and a one year high of $8.38. The company has a market cap of $37.20 million, a price-to-earnings ratio of -2.50 and a beta of 1.30. The company’s fifty day moving average is $4.17 and its 200-day moving average is $4.59.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.03. As a group, equities analysts anticipate that CalciMedica, Inc. will post -2.21 EPS for the current year.

CalciMedica Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.